American Journal of Cardiology
Volume 101, Issue 7 , Pages 953-959 , 1 April 2008

Long-Term (>3 Years) Outcome and Predictors of Clinical Events After Insertion of Sirolimus-Eluting Stent in One or More Native Coronary Arteries (from the Israeli Arm of the e-Cypher Registry)

  • David Planer, MD

      Affiliations

    • Hadassah–Hebrew University Medical Centre, Jerusalem, Israel
    • Corresponding Author InformationCorresponding author: Tel: 972-2-6777111; fax: +972-2-6411028.
    • ,
  • Rafael Beyar, MD, DSc

      Affiliations

    • Rambam Medical Centre, Haifa, Israel
    • ,
  • Yaron Almagor, MD

      Affiliations

    • Shaarei Zedek Medical Centre, Jerusalem, Israel
    • ,
  • Shmuel Banai, MD

      Affiliations

    • Bikur Holim Hospital, Jerusalem, Israel
    • ,
  • Victor Guetta, MD

      Affiliations

    • Sheba Medical Centre, Tel HaShomer, Israel
    • ,
  • Hilton Miller, MD

      Affiliations

    • Tel Aviv Medical Centre, Tel Aviv, Israel
    • ,
  • Ran Kornowski, MD

      Affiliations

    • Rabin Medical Centre, Petah Tikva, Israel
    • ,
  • Simcha Brandes, MD

      Affiliations

    • Laniado Hospital, Netanya, Israel
    • ,
  • Ricardo Krakover, MD

      Affiliations

    • Asaf HaRofeh Medical Centre, Zerifin, Israel
    • ,
  • Mivi Solomon, BA

      Affiliations

    • Israel Heart Society, Tel Aviv, Israel.
    • ,
  • Chaim Lotan, MD

      Affiliations

    • Hadassah–Hebrew University Medical Centre, Jerusalem, Israel

Received 8 August 2007 ,Revised 21 November 2007 ,Accepted 21 November 2007.

References 

  1. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434–1441
  2. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  4. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  5. Cordis Corporation. Cypher® sirolimus-eluting coronary stent—essential prescribing information. http://www.cordis.com/active/crdus/en_US/html/cordis/downloads/CYPHER_EPI_1551787_4.pdfAccessed on June 15, 2007
  6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  7. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46:1002–1005
  8. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–959
  9. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051–1058
  10. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  11. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113
  12. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther. 1997;4:212–224
  13. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?. Circulation. 2000;102:2966–2972
  14. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, et al Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947–953
  15. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478–1481
  16. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med. 2007;356:325–328
  17. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001–2009
  18. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992–2000
  19. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813–818
  20. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  21. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809
  22. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  23. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? (Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents). Circulation. 2007;115:1433–1439
  24. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  25. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  26. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039

PII: S0002-9149(07)02324-7

doi: 10.1016/j.amjcard.2007.11.043

American Journal of Cardiology
Volume 101, Issue 7 , Pages 953-959 , 1 April 2008

Article Tools

* Image Usage & Resolution